Kazia Therapeutics Ltd

Receive alerts
Market Cap:
$21.76 m
52 weeks high
52 weeks low

Viewing results 1-21 of 21


Kazia Therapeutics concludes recruitment into Part B of its phase I ovarian cancer clinical study

About 240,000 women are diagnosed with ovarian cancer each year worldwide and it is the eighth most common cause of cancer death in women. ...

1 week, 2 days ago

Kazia Therapeutics to begin phase I clinical trial for cancer that has spread to the brain

Memorial Sloan Kettering Cancer Center in New York will investigate the potential use of Kazia’s investigational new drug, GDC-0084....

1 month ago

Kazia Therapeutics substantial holder Willoughby Capital increases interest to 17.52%

Edison Investment Research has assigned an indicative valuation range of $84–135 million or $1.35–2.17 per share for Kazia....

on 07/10/2019

Kazia Therapeutics substantial shareholder lifts interest to 17.4%

Sydney-based Hishenk Pty Ltd now holds 10.835 million shares after placement and on-market purchases....

on 07/04/2019

Kazia Therapeutics has two novel classes of anti-cancer drugs: Edison Investment Research

A new collaboration with the Alliance for clinical trials in oncology means Kazia will soon have four clinical trials of GDC-0084 underway in primary or secondary brain cancers. ...

on 06/27/2019

Gold Coast Investment Showcase will feature companies from diverse range of sectors

The conference will be held next Tuesday and Wednesday at Surfers Paradise Marriott Resort & Spa....

on 06/21/2019

Kazia Therapeutics to collaborate with US-based oncology foundation on clinical trials for metastatic brain cancer treatment

The study will mark the fourth ongoing clinical trial for Kazia's GDC-0084 drug candidate, with each trial treating different forms of brain cancer. ...

on 05/19/2019

Kazia Therapeutics gains new substantial holder in The Bank of New York Mellon

The company plans to begin recruitment for its upcoming dose expansion cohort immediately. ...

on 05/08/2019

Kazia Therapeutics' ongoing study confirms higher drug tolerability in newly-diagnosed glioblastoma patients

The company will begin recruitment for the upcoming dose expansion cohort immediately. ...

on 05/06/2019

Kazia Therapeutics studies evaluate therapeutic candidates in ovarian cancer and brain tumours

The oncology-focused biotech is a mid-clinical-stage therapeutics company....

on 05/01/2019

Proactive CEO Sessions in Sydney and Melbourne next week feature five companies

The Sydney session is on Monday, February 18 and the Melbourne session is on the following day, February 19....

on 02/14/2019

Theta Gold Mines to outline South African gold strategy at Proactive CEO Session

The company has near-term catalysts including an upgraded resource statement and a feasibility study....

on 02/11/2019

Kazia Therapeutics will outline anti-cancer drug development strategy at CEO Sessions

The company’s CEO James Garner will present to investors in Sydney and Melbourne....

on 02/06/2019

Anatara Lifesciences to outline its new strategy in human health at Proactive CEO Sessions

Following the successful licencing of its animal health product to Zoetis Inc, Anatara is now focused on building a pipeline of human gastrointestinal health products....

on 02/05/2019

Argonaut Resources to talk Lake Torrens at Proactive CEO Sessions

The company’s CEO Lindsay Owler will address investors at the CEO Sessions....

on 02/05/2019

Peninsula Energy will update on uranium transition progress at Proactive CEO Sessions

The transition to low pH operations at the Lance Projects is expected to enhance recovery and lower operating costs....

on 02/05/2019

AdAlta will outline fibrosis treatment progress during Proactive CEO Sessions

The i-body technology platform of AdAlta is initially focused on treating fibrotic diseases, such as IPF....

on 02/04/2019

Kazia Therapeutics progresses phase II clinical trial for brain cancer drug

There is a global need for new therapies to more effectively treat brain cancer....

on 03/28/2018